Cite

HARVARD Citation

    Honda, M. et al. (n.d.). 479PA phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy for colorectal cancer: The AIRS study. Annals of oncology. p. . [Online]. 
  
Back to record